Hcmi/cmdc sequencing and hcmi searchable catalog (moonshot)
Active Awarded Last action
- Contract number
- HHSN26100040
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,189,724
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $8,189,724.00 Current and potential, with all options
- Completion date 91% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Terminate for Convenience | -$611,128 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $400,343 | |
| Supplemental Agreement for work within scope | $1,621,482 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $6,779,027 |
Show all 13
About this award
The National Cancer Institute awarded an $8.19 million cost-plus-fixed-fee delivery order to Leidos Biomedical Research Inc. for the HCMI/CMDC Sequencing and HCMI Searchable Catalog (Moonshot) project, with performance through September 24, 2027. Work will be performed in Frederick, Maryland, where Leidos operates as a Federally Funded Research and Development Center (FFRDC) contractor for NCI and the National Institutes of Health. This project supports the NCI's broader cancer research initiatives through the provision of sequencing services and development of searchable catalogs related to Human Cell and Molecular Interaction (HCMI) and Cancer Model Development Center (CMDC) research efforts. The contract carries no set-aside designation, reflecting the competitive nature of the award to this specialized biomedical research contractor.
Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc., a large prime federal contractor headquartered in Reston, Virginia, with extensive experience delivering biomedical research and facilities support services across multiple federal agencies. The company has demonstrated substantial capabilities in genetic analysis, sequencing, laboratory testing, and complex scientific research through its existing contract portfolio with NCI and other NIH institutes. This delivery order leverages Leidos' established expertise in advanced genomic technologies and research support infrastructure to advance the NCI's cancer research mission through molecular characterization and accessible data resources.
Quick answers
Who was awarded contract HHSN26100040?
HHSN26100040 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2017.
How much is contract HHSN26100040 worth?
The government has obligated $8,189,724 on HHSN26100040.
Is contract HHSN26100040 an order under another contract?
Yes. HHSN26100040 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100040 competed?
The extent of competition for HHSN26100040 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award